REFERENCES
- Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Contraception 1998; 58:345–9
- Bringer J, Lefebvre P, Hédon B, Delchabre J. The effect of monophasic and triphasic oral contraceptives con- taining gestodene and desogestrel on body weight and composition. Gynecol Endocrinol 1996; 10(Suppl 5): 53–60
- Reubinoff B, Berry E, Gubstein A, et al. Effects of low-dose estrogen oral contraceptive on weight, body composition, and fat distribution in young women. Fertil Steril 1995;63:516–21
- Greil H. Normal weight and optimal weight descrip- tion and evaluation of body mass. Anthropol Anz 1998; 56:312–14
- Obesity in Europe: scaling and epidemic. Int J Obes Relat Metab Disord 1995; 19(Suppl 3):S1
- Gulliford MC, Fona RJ, Chinn S. Trends in body mass index in young adults in England and Scotland from 1973 to 1988. J Epidemiol Community Health 1992; 46:187–90
- Kuskowska WA, Bergstrom R. Trends in body mass index and prevalence of obesity in Swedish women 1980–89. J Epidemiol Community Health 1993;47:195–9
- Carpenter S, Neinstein LS. Weight gain in adolescent and young adult oral contraceptive users. J Adolesc Health Care 1986;7:342–4
- Elstein M, Furniss H. Advances in oral hormonal contraception. Zentralbl Gynecol 1995;117:559–65
- Haapanen N, Miilunpalo S, Pasanen M, et al. Associa- tion between leisure time physical activity and 10-year body mass change among working-aged men and women. Int J Obes Relat Metab Disord 1997;21:288–96
- Endrikat J, Müller U, Düsterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mg ethinylestradiol/75 mg gestodene and 30 mg ethinylestradiol/75 mg gestodene, with respect to efficacy, cycle control and tolerance. Contraception 1997;55:131–7
- Endrikat E, Düsterberg B, Ruebig A, et al. Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999;60:269–74
- Düsterberg B, Ellman H, Müller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contra- ceptive containing gestodene. Gynecol Endocrinol 1996; 10:33–9